Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 142Breast Neoplasms 97Lung Neoplasms 72Brain Neoplasms 67Glioblastoma 59Carcinoma, Non-Small-Cell Lung 54Glioma 52Pancreatic Neoplasms 39Neoplasms 39Neoplasm Metastasis 36Colorectal Neoplasms 31Carcinoma, Hepatocellular 30Lymphoma, Large B-Cell, Diffuse 27Carcinoma, Renal Cell 27Multiple Myeloma 26Squamous Cell Carcinoma of Head and Neck 25Rectal Neoplasms 21Melanoma 21Ovarian Neoplasms 20Astrocytoma 20Urinary Bladder Neoplasms 18Lymphoma, Follicular 18Uterine Cervical Neoplasms 17Colonic Neoplasms 17Head and Neck Neoplasms 16Lymphoma 15Esophageal Neoplasms 15Sarcoma 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 14

Interventions

pembrolizumab 1Magnetic Resonance Spectroscopy 1Ferrosoferric Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Carcinoma Metastatic in the Brain × Magnetic Resonance Spectroscopy × Clear all
NCT03325166 2022-08-10

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled 8 charts

Lung Carcinoma Metastatic in the Brain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡